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Proteinuria is a primary clinical symptom of a large number
of glomerular diseases that progress to end-stage renal
failure. Podocyte dysfunctions play a fundamental role in
defective glomerular filtration in many common forms of
proteinuric kidney disorders. Since binding of these cells to
the basement membrane is mediated by integrins, we
determined the role of integrin-linked kinase (ILK) in
podocyte dysfunction and proteinuria. ILK expression was
induced in mouse podocytes by various injurious stimuli
known to cause proteinuria including TGF-b1, adriamycin,
puromycin, and high ambient glucose. Podocyte ILK was also
found to be upregulated in human proteinuric glomerular
diseases. Ectopic expression of ILK in podocytes decreased
levels of the epithelial markers nephrin and ZO-1, induced
mesenchymal markers such as desmin, fibronectin, matrix
metalloproteinase-9 (MMP-9), and a-smooth muscle actin
(a-SMA), promoted cell migration, and increased the
paracellular albumin flux across podocyte monolayers. ILK
also induced Snail, a key transcription factor mediating
epithelial–mesenchymal transition (EMT). Blockade of ILK
activity with a highly selective small molecule inhibitor
reduced Snail induction and preserved podocyte phenotypes
following TGF-b1 or adriamycin stimulation. In vivo, this ILK
inhibitor ameliorated albuminuria, repressed glomerular
induction of MMP-9 and a-SMA, and preserved nephrin
expression in murine adriamycin nephropathy. Our results
show that upregulation of ILK is a convergent pathway
leading to podocyte EMT, migration, and dysfunction. ILK
may be an attractive target for therapeutic intervention of
proteinuric kidney diseases.
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Proteinuria, the clinical manifestation of a defective glomer-
ular filtration, is an early hallmark of a large number of
glomerular diseases that progress to end-stage kidney
failure.1,2 Glomerular filtration barrier consists of fenestrated
endothelium, glomerular basement membrane, and termin-
ally differentiated podocytes, which possess sophisticated
foot processes that extend toward the capillaries to which
they affix.3 Podocyte foot processes interdigitate with the
counterparts of their neighboring cells to form filtration
slits, known as the slit diaphragm. This membrane-like
structure constitutes the final barrier to protein loss during
the convective fluid flow from vascular to urinary space
of the capillary wall.4,5 In this context, the slit diaphragm
of podocyte foot processes is the major determinant of
the size permselectivity of glomerular filtration barrier.
Accordingly, any injury to podocytes that disrupts the
structural and functional integrity of the slit diaphragm
would eventually lead to a defective glomerular filtra-
tion, thereby causing proteinuria in various pathologic
circumstances.
Podocytes are susceptible to injury as seen in many forms
of glomerular diseases, including diabetic nephropathy, focal
segmental glomerulosclerosis, membranous glomerulopathy,
and lupus nephritis.6–8 How injurious stimuli cause podocyte
damage leading to proteinuria, however, remains elusive and
controversial. A prevalent view in the field emphasizes on the
importance of podocyte depletion, resulted from the
detachment from the glomerular basement membrane
and/or apoptosis, as a causative factor for the onset of
proteinuria.2,9–12 Emerging evidence also suggests that
podocytes could undergo a phenotypic conversion after
injury, characterized by losing its epithelial features such as
nephrin, P-cadherin, and ZO-1, while acquiring mesenchy-
mal markers such as desmin, fibroblast-specific protein-1,
matrix metalloproteinase-9 (MMP-9), type I collagen, and
fibronectin.13–15 This epithelial–mesenchymal transition
(EMT) will render podocytes motile and ultimately lead to
the disruption of the delicate three-dimensional architecture
of podocytes, thereby impairing their filtration barrier
function.16 However, the underlying mechanism as well as
the intracellular mediator that governs podocyte EMT under
pathologic conditions remains largely unknown.
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Integrin-linked kinase (ILK) is an ankyrin repeat-contain-
ing serine/threonine protein kinase that interacts with the
cytoplasmic domains of b1 and b3 integrins and mediates the
integrin signaling.17,18 ILK has been shown to have an
essential role in podocyte biology, as conditional knockout of
its gene in a podocyte-specific manner leads to massive
proteinuria, glomerulosclerosis, kidney failure, and prema-
ture death in mice.19,20 Aberrant regulation of ILK is also
implicated in the pathogenesis of various proteinuric kidney
diseases including diabetic nephropathy, congenital nephritic
syndrome, experimental models of glomerular disease.21–23
In addition, ILK is shown to be a key intracellular mediator
that controls EMT in tubular epithelial cells.24 These
observations point to a possible connection among aberrant
ILK regulation, podocyte EMT, dysfunction, and proteinuria.
In this study, we have investigated the regulation and
function of ILK in cultured podocytes and in mouse model
of podocyte injury induced by adriamycin (ADR). We found
that ILK expression in podocytes is increased in response
to various injurious stimuli, and ectopic expression of
ILK induces Snail and mesenchymal conversion of podocytes.
Furthermore, administration of a small molecule ILK inhi-
bitor in vivo ameliorates albuminuria and protects podo-
cytes from injury. Our results indicate that increased ILK has
a role in mediating podocyte dysfunction, and thus targeting
this signaling could be an attractive strategy for therapeutic
intervention of proteinuric kidney diseases.
RESULTS
Upregulation of ILK in podocytes after various injuries
To investigate the potential role of ILK in podocyte
dysfunction, we evaluated the effects of various extracellular
cues on ILK expression in cultured mouse podocytes. As
shown in Figure 1a and b, transforming growth factor (TGF)-b1
induced ILK expression in a time-dependent manner, and
substantial increase in ILK protein level was observed at 24 h
after TGF-b1 stimulation. Dose–response studies revealed
that TGF-b1 at 2 ng/ml induced maximal expression of ILK,
and further increase in TGF-b1 beyond this concentration
did not result in additional induction (Figure 1c). Immuno-
fluorescence staining also showed a dramatic induction of
ILK after TGF-b1 treatment (Figure 1d). ILK was localized
primarily in the focal adhesion sites that have close contacts
between the substrate and the plasma membrane on the basal
surface of podocytes (Figure 1d, arrowheads). Of interest, b1
integrin, the upstream regulator of ILK, was also upregulated
in the injured podocytes after TGF-b1 treatment (Figure 1e).
We also examined ILK expression in podocytes after
treatment with various injurious stimuli. As shown in
Figure 2, ADR, a well-known agent that specifically damages
podocytes and causes proteinuria in vivo,25,26 induced ILK
expressions in a time- and dose-dependent manner. Similarly,
puromycin aminonucleoside (PAN) also induced ILK
expression in podocytes (Figure 2c and d). The induction
of ILK in podocytes occurred rapidly, beginning between 1
and 6 h after ADR or PAN treatment (Figure 2a and c). We
found that high ambient glucose condition also induced ILK
expression in a delayed manner, compared with normal
glucose condition or mannitol controls (Figure 2e). Together,
these results suggest that upregulation of ILK is a common
response of podocytes following different stresses/injuries.
Specific induction of ILK in podocytes in primary glomerular
diseases
To explore the relevance of ILK regulation to podocyte
dysfunction in vivo, we examined ILK protein expression in
the glomeruli of human kidneys with primary glomerular
diseases. Immunohistochemical staining showed little ILK
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Figure 1 | TGF-b1 induces ILK and b1 integrin expression in mouse podocytes. (a–c) Western blot analyses show that TGF-b1 induced
ILK expression in cultured podocytes in a time- and dose-dependent manner. Podocytes were incubated with 2 ng/ml of TGF-b1 for
various periods of time as indicated (a, b) or with different concentrations of TGF-b1 for 48 h (c). Quantitative determination of relative ILK
levels in different times after TGF-b1 treatment was presented in (b). *Po0.05 versus controls (n¼ 3). (d) Immunofluorescence staining
showed ILK induction by TGF-b1 in podocytes. ILK protein was specifically localized at the focal adhesion sites of podocytes (arrowheads).
(e) TGF-b1 (2 ng/ml) also induced b1 integrin expression in mouse podocytes. GAPDH, glyceraldehyde 3-phosphate dehydrogenase; ILK,
integrin-linked kinase; TGF-b1, transforming growth factor-b1.
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protein in normal glomeruli of human kidneys (Figure 3a).
However, ILK protein was upregulated in the glomeruli of
kidney biopsies from patients with focal segmental glomer-
ulosclerosis (Figure 3b and c). On the basis of anatomical
location and morphology, these ILK-positive cells appeared
to be podocytes. Similarly, ILK was also upregulated in the
glomerular podocytes in kidney biopsies from patients with
diabetic nephropathy (Figure 3d). To confirm ILK induction in
podocytes, we used a double immunostaining for ILK (red) and
podocyte marker synaptopodin (green) in diabetic nephropathy.
As shown in Figure 3e and f, colocalization of ILK and
synaptopodin was evident; and ILK-positive cells were pre-
dominantly positioned outside the glomerular basement mem-
brane outlined by synaptopodin in the glomeruli (Figure 3f,
arrowheads). These results suggest that ILK is specifically
upregulated in the glomerular podocytes of human kidneys
with primary glomerular diseases, in which podocyte dysfunc-
tion and proteinuria are the major characteristic features.
Ectopic expression of ILK induces podocyte EMT, migration,
and Snail expression
To examine the potential role of ILK induction in podocytes,
we investigated the impact of ILK overexpression on
podocyte phenotypes and function. Mouse podocytes were
infected with adenoviral vector that harbors Flag-tagged
ILK gene (Ad.Flag-ILK) or control adenovirus containing
b-galactosidase gene (Ad.LacZ), respectively. As shown in
Figure 4a, ectopic expression of exogenous ILK suppressed
epithelial ZO-1 expression, and induced desmin, a-smooth
muscle actin (a-SMA) and fibronectin expression in
Figure 3 | Induction of ILK protein in the glomerular podocytes in patients with proteinuric kidney diseases. Immunohistochemical
staining showed strong ILK expression in the glomerular podocytes of patients with proteinuric kidney diseases. (a) normal kidney;
(b) focal segmental glomerulosclerosis; (c) focal segmental glomerulosclerosis; (d) diabetic nephropathy. (e) Double immunofluorescence
staining shows ILK localization in glomerular podocytes. Kidney biopsies from patients with diabetic nephropathy were double
immunostained for ILK (red) and podocyte marker synaptopodin (green). (f) Enlarged box area in (e). Arrowheads indicate positive staining.
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Figure 2 | Induction of ILK expression in podocytes in response to various injurious stimuli. Podocytes were treated with 2 mg/ml
of adriamycin (a) or with 1 mg/ml of puromycin aminonucleoside (c) for various periods of time as indicated, or with increasing amounts of
ADR (b) and PAN (d) for 12 h. Podocytes were also incubated with high glucose (30mM) for different periods of time as indicated (e).
Both normal glucose (5mM) and mannitol (5mM normal glucose and 25mM mannitol) were used as controls and harvested at 9 days.
Cell lysates were immunoblotted with antibodies against ILK and housekeeping proteins. ADR, adriamycin; Cont. Man., control mannitol;
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; ILK, integrin-linked kinase; PAN, puromycin aminonucleoside.
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podocytes, as shown by immunofluorescence staining. Flag-
tagged ILK expression, as well as desmin, a-SMA and
fibronectin induction after adenoviral vector infection, was
confirmed by western blot analysis (Figure 4b). Real-time
RT-PCR revealed that ectopic expression of ILK suppressed
nephrin expression (Figure 4c). In addition, exogenous ILK
also induced MMP-9 expression and secretion, which formed
protein aggregates localized on podocyte surface (Figure 4a).
These data suggest that forced expression of ILK in podocytes
causes a phenotypic change that is reminiscent of EMT.13
Podocytes after EMT may become motile with an
increased migratory capacity. To test this hypothesis, we
examined the effect of ILK on podocyte migration by using a
Boyden chamber motility assay. As shown in Figure 4d and e,
ectopic expression of ILK significantly increased the migra-
tory ability of podocytes across the pores of the Transwell
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Figure 4 | Ectopic expression of ILK induces podocyte EMT, migration, and Snail expression. (a) Immunofluorescence staining showed
that exogenous ILK expression resulted in suppression of ZO-1 and induction of mesenchymal marker desmin, a-SMA, fibronectin, and
MMP-9 in podocytes. Podocytes were infected with adenovirus harboring either Flag-ILK (Ad.Flag-ILK) or b-galactosidase gene (Ad.LacZ).
Overexpression of exogenous ILK (Flag-ILK) and induction of desmin, a-SMA and fibronectin in podocytes were also confirmed by western
blot analysis (b). Of note, infection with control adenovirus (Ad.LacZ) did not significantly affect the basal expression of ILK, desmin, a-SMA
and fibronectin. (c) Real-time RT-PCR showed that ectopic expression of exogenous ILK inhibited nephrin mRNA expression. Relative mRNA
level over the Ad.LacZ controls (value¼ 1.0) is presented. *Po0.05 (n¼ 6). (d, e) Forced expression of ILK promoted podocyte migration.
Representative micrographs show podocyte migration in a Boyden chamber motility assay (d). Quantitative determination of the migrated
podocytes per field in different groups is presented (e). *Po0.05 (n¼ 3). (f) Ectopic expression of ILK induced Snail expression. Cell lysates
were prepared at 48 h after infection with Ad.Flag-ILK or Ad.LacZ adenovirus, and immunoblotted with antibodies against Snail and
a-tubulin, respectively. Cells without infection with adenovirus were denoted as control. (g) Overexpression of ILK impaired the filtration
barrier function of podocytes. Podocyte monolayer on collagen-coated Transwell filters was infected with Ad.LacZ or Ad.Flag-ILK
adenovirus, and 24 h later albumin permeability across podocyte monolayer was determined. Data are presented as means±s.e.m. (n¼ 6).
*Po0.01 versus Ad.LacZ control. a-SMA, a-smooth muscle actin; EMT, epithelial–mesenchymal transition, GAPDH, glyceraldehyde
3-phosphate dehydrogenase; ILK, integrin-linked kinase; MMP-9, matrix metalloproteinase-9.
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filters, suggesting that podocyte EMT induced by ILK is
accompanied by an enhanced cell migration.
To explore the potential mechanism underlying ILK regu-
lation of podocyte EMT, we examined the expression of Snail,
a key transcription factor that is crucial in controlling EMT
in various circumstances. As shown in Figure 4f, ectopic
expression of exogenous ILK indeed induced Snail expression
in podocytes.
We next examined whether ILK overexpression affects the
barrier function of podocyte monolayer. To this end, we used
a simple, paracellular albumin flux assay that assesses the
albumin filtration across the monolayer of cultured differentiated
podocytes. As shown in Figure 4g, an increased albumin flux
was observed in the podocytes infected with adenovirus
containing ILK gene (Ad.Flag-ILK), when compared with
that infected with control adenovirus (Ad.LacZ). These
results indicate that ILK overexpression results in a defective
filtration barrier and impairs podocyte function.
Inhibition of ILK blocks Snail induction and preserves
podocyte phenotypes after injury in vitro
We next sought to examine whether inhibition of ILK prevents
podocyte dysfunction after injury. To test this, we used a highly
selective small molecule ILK inhibitor, QLT0267, that has been
shown to inhibit ILK signaling in various types of cells.27–29 The
specificity and potency of QLT0267 in inhibiting ILK activity
are also shown in kidney tubular epithelial cells.29 As shown
in Figure 5a, QLT0267 selectively inhibited the phosphorylation
of glycogen synthase kinase (GSK)-3b, a major downstream
substrate of ILK, in podocytes after TGF-b1 stimulation.
However, it did not significantly affect the phosphorylation
and activation of Smad3 and p38 mitogen-activated protein
kinase induced by TGF-b1 (Figure 5a).
Figure 5b shows that QLT0267 effectively blocked Snail
expression induced by ILK in podocytes, suggesting that
blockade of ILK signaling by QLT0267 is able to inhibit a key
EMT initiator gene. Consistently, simultaneous incubation
of podocytes with QLT0267 also largely abolished the TGF-
b1-mediated induction of desmin, fibronectin, and MMP-9
(Figure 5c–e), thereby preserving podocyte phenotypes.
Inhibition of ILK by QLT0267 also ameliorated podocyte
injury induced by ADR, as shown in Figure 6. Mesenchymal
transition of podocytes was evident after treatment with
ADR, as illustrated by induction of a-SMA, desmin, fibro-
nectin, and MMP-9 (Figure 6a). These phenotypic alterations
were largely prevented by inhibition of ILK with QLT0267
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(Figure 6a–c). Hence, ILK could be a therapeutic target for
ameliorating ADR-mediated podocyte EMT and dysfunction.
Inhibition of ILK ameliorates podocyte injury and prevents
albuminuria in vivo
We further investigated the role of ILK in podocyte injury
and proteinuria in vivo by using mouse model of ADR
nephropathy. Male BALB/c mice received a single intravenous
injection of ADR, and ILK was dramatically upregulated in
the isolated glomeruli at 7 days after ADR administration
(Figure 7a). Massive albuminuria developed in these mice;
and interestingly, daily intraperitoneal administration of
QLT0267 significantly ameliorated albuminuria in a dose-
dependent manner (Figure 7b). QLT0267 at 5mg/kg body
weight suppressed urine albumin excretion by about 75%,
compared with the vehicle controls. Of note, QLT0267 has no
adverse effect on normal kidney structure and function.29
Figure 8 shows that inhibition of ILK with QLT0267 also
ameliorated podocyte injury in ADR nephropathy in vivo.
Glomeruli were isolated from mouse kidneys after various
treatments, and glomerular MMP-9, a-SMA, and nephrin
expression was analyzed by western blot analyses. Consistent
with in vitro data, ADR-induced MMP-9 and a-SMA
expression in mouse glomeruli, and inhibition of ILK by
QLT0267 abrogated their induction (Figure 8a–c). In
addition, we found that nephrin expression was suppressed
in the glomeruli in ADR nephropathy, compared with nor-
mal controls. Consistently, QLT0267 significantly preserved
glomerular nephrin expression after ADR injection (Figure
8a and d). Confocal microscopy revealed that whereas
nephrin mostly disappeared in ADR-injected mice, it was
largely preserved along glomerular basement membrane in
the glomeruli after QLT0267 treatment (Figure 8e). Figure 8f
shows the quantitative determination of nephrin loss (injury
score) in different groups. These data suggest that targeting
ILK by small molecule inhibitor is able to ameliorate
podocyte injury and prevent proteinuria in vivo.
DISCUSSION
Despite remarkable advances in our understanding of the
pathogenesis of proteinuria in patients with genetic,
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congenital nephrotic syndrome,4,7 how injurious stimuli
cause podocyte damage in many acquired forms of
proteinuric kidney diseases such as focal segmental glomer-
ulosclerosis and diabetic nephropathy remains poorly under-
stood. We recently propose that podocytes after injury may
undergo a phenotypic conversion that is reminiscent of
EMT.13 Such a phenotypic alteration would certainly cause
podocytes to lose their multifaceted morphologic architec-
ture and to relinquish their highly specialized functions,
which undoubtedly impairs the integrity of glomerular filtra-
tion barrier, leading to the onset of proteinuria. In this study,
we have further identified ILK as an important intracellular
mediator that controls podocyte EMT. Our results indicate
that ILK expression in podocytes is increased in response
to various injurious stimuli, and ectopic expression of
ILK induces key EMT-regulatory gene Snail and promotes
podocyte dedifferentiation, migration, and dysfunction.
Conversely, specific inhibition of ILK activity by a highly
selective small molecule inhibitor ameliorates albuminuria
and protects podocytes from injury induced by ADR in vivo.
These findings provide significant insights into the mecha-
nism underlying podocyte dysfunction in pathologic states,
and indicate ILK as a potential therapeutic target for the
treatment of proteinuric kidney diseases.
ILK is known to have a central role in regulating a wide
variety of cellular processes such as cell adhesion, survival,
EMT, and extracellular matrix deposition.24,30,31 The importance
of ILK in podocyte biology is also illustrated clearly in
conditional knockout mice in which ILK gene is specifically
disrupted in podocytes.19,20 On the other hand, aberrant
regulation of ILK occurs in various proteinuric kidney
diseases such as nephrotic syndrome, diabetic nephropathy,
and experimental models of nephropathies induced by
ADR and PAN,21–23 indicating a close connection between
upregulation of ILK and podocyte dysfunction. Notably, ILK
expression in podocytes is induced after treatment with a
diverse type of injurious stimuli including TGF-b1, ADR,
PAN, and high ambient glucose condition (Figures 1 and 2),
as well as angiotensin II.32 ILK is also upregulated in the
glomeruli of mouse model of podocyte injury induced by
ADR (Figure 7a) and in patients with diabetic nephropathy
and focal segmental glomerulosclerosis (Figure 3), two
common kidney diseases characterized by prominent protei-
nuria. As these injurious mediators, including fibrogenic
cytokines, toxic, and metabolic factors, are considered as the
principal causes of proteinuria, it is conceivable to speculate
that increased ILK expression is a common response of
podocytes after various injuries, and represents a convergent
pathway that mediates podocyte dysfunction and proteinuria
under different pathologic conditions. Interestingly, b1
integrin is also induced in podocytes after incubation with
TGF-b1 (Figure 1e) and high glucose.32 Given that b1
integrin is a major upstream regulator of ILK, the
simultaneous induction of both b1 integrin and ILK likely
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leads to an amplification of ILK signaling during podocyte
injury.
ILK is well documented as a key intracellular mediator
that promotes EMT in different cell systems including
tubular epithelial cells.24,33 As podocytes are capable of
undergoing EMT after injury as recently shown,13,14 the
upregulation of ILK in podocytes by a diverse array of
injurious stimuli supports the notion that phenotypic
alteration could be a potential pathway leading to podocyte
dysfunction. Consistent with this view, ectopic expression of
exogenous ILK in podocytes not only suppresses nephrin and
epithelial ZO-1 expression, but also induces the de novo
expression of numerous mesenchymal markers including
desmin, a-SMA, fibronectin, and MMP-9 (Figure 4). These
alterations in cell–cell adhesion (nephrin and ZO-1) and
cytoskeleton (desmin and a-SMA) proteins will lead to
disruption of the slit diaphragm integrity. Interestingly,
ectopic expression of ILK renders podocytes to be motile,
with an increased migration capacity (Figure 4). This
enhanced motility of podocytes after ILK expression could
be a part of or a consequence of EMT, which presumably
leads to a disruptive glomerular filtration barrier. Indeed,
overexpression of ILK impairs the filtration barrier function
of podocyte monolayer in a paracellular albumin flux assay
(Figure 4). Taken together, our results indicate that
upregulation of ILK is sufficient to cause podocyte pheno-
typic alteration and migration, which is associated with an
impaired filtration barrier function.
Although the molecular details by which ILK induces
podocyte EMT remain to be elucidated, it seems to be related
to its ability to induce Snail expression. ILK is reported to
phosphorylate its downstream targets, such as GSK-3b.34
Phosphorylation of GSK-3b causes its inactivation, which
eventually leads to Snail upregulation by different mechan-
isms. On one hand, inhibition of GSK-3b induces Snail
protein stabilization by preventing its phosphorylation and
subsequent ubiqutin-mediated degradation;35 on the other
hand, GSK-3b inactivation also stabilizes b-catenin, resulting
in its nuclear accumulation, wherein it associates with T-cell
factor /lymphoid enhancer-binding factor to regulate Snail
gene transcription.36–38 Consistent with this notion, recent
studies show that b-catenin upregulates Snail mRNA
expression in mouse podocytes.26 Hence, ILK-mediated
GSK-3b inactivation is able to induce Snail protein expres-
sion through both transcriptional and post-translational
mechanisms. Accordingly, ectopic expression of ILK mark-
edly induces Snail expression, and inhibition of ILK activity
by QLT0267 suppresses Snail induction and blocks TGF-b1-
and ADR-induced mesenchymal conversion of podocytes
(Figures 5 and 6). Intriguingly, it has been recently
shown that Snail directly inhibits nephrin expression in
podocytes;26,39 and fibroblast-specific protein-1-positive
podocytes in the urine sediments of patients with diabetic
nephropathy selectively express ILK and Snail.14 In concert,
these results point to a critical role of ILK/Snail signaling in
mediating podocyte EMT and dysfunction.
This study shows that ILK could be an attractive
therapeutic target for the treatment of proteinuric kidney
diseases. In mouse model of ADR nephropathy, intraper-
itoneal injection of QLT0267 suppresses albuminuria in a
dose-dependent manner (Figure 7). This beneficial effect of
QLT0267 is accompanied by a dose-dependent suppression of
MMP-9 and a-SMA, and a preservation of nephrin
expression in the isolated glomeruli of mice after ADR
treatment (Figure 8). Therefore, inhibition of ILK activity
in vivo also blocks the expression of mesenchymal markers
(a-SMA and MMP-9), while prevents loss of podocyte-
specific nephrin, consistent with a role of ILK in mediating
podocyte phenotypic alteration. The biologic actions of ILK
are mediated through its dual functions: as an adapter/
scaffolding protein and as a signaling protein.30,40 As an
adapter protein, ILK assumes an important role in normal
podocyte biology by bridging the integrin and slit diaphragm
signaling through formation of a ternary complex with
nephrin.20 However, it appears that the function of ILK as an
adapter protein in normal physiologic states is independent
of its signaling activity, as QLT0267 treatment of normal mice
neither disrupts ILK/nephrin interaction nor induces podo-
cyte lesions.29
In summary, we have shown in this study that upregu-
lation of ILK is a common response of podocytes after a
diverse array of injuries, which may have a role in mediating
podocyte EMT, migration, and dysfunction. It should be stressed
that this study has some limitations and pitfalls, as it only used
an established, transformed podocyte cell line and a single
animal model of podocyte injury induced by ADR. Whether
these results can extend to primarily cultured podocytes and
other proteinuric kidney diseases such as diabetic nephropathy
remains to be determined. Nevertheless, our data provide a
proof of principle that targeting ILK/Snail pathway with small
molecule inhibitor might be an attractive therapeutic strategy for
the treatment of proteinuric kidney disorders.
MATERIALS AND METHODS
Cell culture and treatment
Mouse conditionally immortalized podocyte cell line was described
previously.41 Cells were cultured on dishes coated with type I
collagen (Sigma, St Louis, MO, USA) and in RPMI 1640 medium
supplemented with 10% fetal bovine serum, 100U/ml penicillin,
and 100U/ml streptomycin at 33 1C in the presence of 50U/ml
mouse recombinant g-interferon (Invitrogen, Carlsbad, CA, USA).
To induce differentiation, we grew podocytes under nonpermissive
conditions at 37 1C in the absence of interferon-g for 10–14 days, as
previously established.41 Podocytes were treated under differentiat-
ing condition in serum-free medium with TGF-b1 (R&D Systems,
Minneapolis, MN, USA), ADR (doxorubicin hydrochloride; Sigma),
PAN, and high glucose (Sigma) at different concentrations for
various periods of time as indicated. For high-glucose treatment,
glucose was added to the glucose-free medium to final concentra-
tions of 5mM (normal glucose) or 30mM (high glucose), respec-
tively. Mannitol was used as controls (5mM glucoseþ 25mM
mannitol). Podocytes were refed with fresh medium containing
high glucose or mannitol every 3 days.
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Animal studies
Male BALB/c mice weighing 20–22 g were obtained from Harlan
Sprague Dawley (Indianapolis, IN, USA) and housed in the animal
facilities of the University of Pittsburgh Medical Center, with free
access to food and water. Animals were treated humanely by use of
the protocols approved by the institutional animal use and care
committee at the University of Pittsburgh. Mice were injected
through the tail vein with ADR at the dosage of 12mg/kg body
weight in saline solution. Small molecule ILK inhibitor QLT0267
(generously provided by QLT, Vancouver, BC, Canada) was
administered by daily intraperitoneal injection at the doses of 0.5,
2.0, and 5.0mg/kg body weight. As a control, a group of ADR mice
was injected with the same volume of vehicle (5% Tween 80 in 0.9%
saline). Animals were killed at day 7 after ADR injection. The
kidneys were removed for various analyses. One part of the kidney
was fixed in 10% phosphate-buffered formalin, followed by paraffin
embedding for histologic and immunohistochemical studies.
Another part of kidneys was used to isolate renal glomeruli by a
sequential sieving technique as described previously.42 The third
part was snap-frozen in liquid nitrogen, and stored at 80 1C for
cryosections and protein extractions.
Adenovirus infection
Podocytes were seeded in complete medium on six-well plates, and
infected with adenovirus that harbors Flag-tagged ILK gene (Ad.Flag-
ILK),43 or the control adenovirus containing b-galactosidase gene
(Ad.LacZ) at a concentration of 2 or 4 107 particles per ml. Infected
cells were incubated for 6 h, and then restored to complete medium.
After 48 h, whole-cell lysates were collected for real-time RT-PCR and
western blot analyses. Infected cells were also subjected to immuno-
fluorescence staining with different antibodies, respectively.
Western blot analysis
Proteins in cell and glomerular lysates were separated on
SDS–polyacrylamide gel electrophoresis and detected by western
blot analysis according to the established protocols described
previously.44 The primary antibodies used were as follows: anti-
ILK (Upstate, Charlottesville, VA, USA), anti-b1 integrin (cat. no.
610468), anti-fibronectin (clone 10) (BD Transduction Laboratories,
Lexington, KY, USA), anti-MMP-9, anti-a-SMA (clone 1A4), anti-
a-tubulin (T-9026) (Sigma), anti-desmin (MP Biomedicals, Solon,
OH, USA), anti-Snail (Ab17732; Abcam, Cambridge, MA, USA),
anti-phosphorylated GSK-3b (cat. no. 9336), total GSK-3b (cat. no.
9315), anti-phosphorylated Smad3 (cat. no. 9514), anti-phosphory-
lated p38 mitogen-activated protein kinase (cat. no. 4631) (Cell
Signaling Technology, Danvers, MA, USA), anti-nephrin (Fitzgerald
Industries International, Concord, MA, USA), anti-Smad1/2/3 (sc-
7960), anti-actin (sc-1616) (Santa Cruz Biotechnology, Santa Cruz,
CA), anti-glyceraldehyde 3-phosphate dehydrogenase (Ambion,
Austin, TX, USA).
Immunofluorescence staining
Podocytes grown on type I collagen-coated cover-slips and kidney
cryosections at 4-mm thickness were fixed for 15min at room
temperature in 4% paraformaldehyde, followed by permeabilization
with 0.2% Triton X-100 in phosphate-buffered saline for 10min.
After blocking with 10% normal donkey serum in phosphate-
buffered saline for 30min, cells and kidney sections were incubated
with primary antibodies against ILK, fibronectin, a-SMA, desmin,
MMP-9, ZO-1, nephrin, and podocalyxin (Zymed, Carlsbad, CA,
USA). Nonimmune immunoglobulin G served as a negative control,
and no staining was observed. The slides were viewed under Eclipse
E600 epifluorescence microscope, or Leica TCS-SL confocal
microscope. A semiquantitative scoring was performed to determine
the severity of injury. Score 0 represents no lesion, 1, 2, 3, and 4
represent the lesion involving o25, 25–50, 50–75, and 475%
of the glomerular tuft area, respectively. At least 10 glomeruli
were randomly selected for each mouse and then an average
of composite score was calculated. Three mice from each group
were analyzed.
Immunostaining for human kidney specimens
Human kidney specimens were obtained from diagnostic renal biopsy
performed at the University of Pittsburgh Medical Center. As normal
controls, nontumor kidney tissue from the patients who had renal cell
carcinoma and underwent nephrectomy was used. Studies using human
tissues were approved by the institutional review board at the University
of Pittsburgh. Immunohistochemical staining was performed using
established procedures as described previously.13,45 Briefly, paraffin-
embedded kidney sections from patients were prepared by a routine
procedure and stained with the specific primary antibody against ILK
(Upstate). As a negative control, the primary antibody was replaced with
nonimmune goat immunoglobulin G, and no staining occurred. To
confirm ILK expression in podocytes, we performed double immuno-
fluorescence staining for ILK and podocyte marker synaptopodin on
human kidney specimens. Briefly, paraffin-embedded kidney sections
were incubated with primary antibodies against ILK and synaptopodin
(Progen, Heidelberg, Germany), followed by staining with FITC- and
CY3-conjugated secondary antibodies. Stained samples were viewed
using an Eclipse E600 epifluorescence microscope equipped with a
digital camera (Nikon, Melville, NY, USA).
Real-time RT-PCR
For quantitative determination of nephrin mRNA levels, a real-time
RT-PCR was performed on ABI PRISM 7000 Sequence Detection
System (Applied Biosystems, Foster City, CA, USA), as described
previously.29 Total RNA was extracted using TRIzol RNA isolation
system (Invitrogen). The first strand of cDNA was synthesized using
2 mg RNA in 20 ml of reaction buffer by RT using AMV-RT
(Promega, Madison, WI, USA) and random primers at 42 1C for
30min. The PCR reaction mixture in a 25 ml volume contained
12.5ml 2 SYBR Green PCR Master Mix (Applied Biosystems), 5 ml
diluted RT product (1:10), and 0.5 mM sense and antisense primer
sets. The sequences of b-actin primer pairs used in real-time PCR
were described previously.29 The sequences of nephrin primer pairs
were as follows: 50-cccaggtacacagagcacaa (sense), and 50-ctcacgctca
caaccttcag (antisense). PCR reaction was run under standard
conditions. After sequential incubations at 50 1C for 2min and
95 1C for 10min, respectively, the amplification protocol consisted
of 50 cycles of denaturing at 95 1C for 15 s, annealing and extension
at 60 1C for 60 s. The standard curve was constructed from series
dilutions of template cDNA. The nephrin mRNA levels were
calculated after normalizing with b-actin.
Boyden chamber motility assay
Cell motility and migration were evaluated using Boyden chamber
motogenicity assay with tissue culture-treated Transwell filters
(Corning Costar Corporation, Cambridge, MA, USA), as described
previously.46 Podocytes after infection with Ad.Flag-ILK or Ad.LacZ
adenovirus were seeded onto the filters (8mm pore size) in the top
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compartment of the chamber. After 2 days of incubation at 37 1C
filters were fixed with 3% paraformaldehyde in phosphate-buffered
saline, and stained with 0.1% Coomassie blue in 10% metha-
nol–10% actic acid, and the upper surface of the filters was carefully
wiped with a cotton-tipped applicator. Cells that passed through the
pores were counted in three nonoverlapping  20 fields and
photographed with a Nikon microscope.
Albumin influx assay
Albumin filtration assay was performed by measuring the transe-
pithelial passage of bovine serum albumin from bottom to top
compartment of the Transwell chambers (0.4 mm pore; Corning
Costar Corporation) as described previously.47–49 Confluent differ-
entiated podocytes were exposed to adenovirus containing ILK gene
(Ad.Flag-ILK) or control adenovirus (Ad.LacZ) for 48 h. Cells were
washed twice with phosphate-buffered saline supplemented with
1mM MgCl2 and 1mM CaCl2 to preserve the cadherin-based
junctions. The top chamber was then refilled with 0.15ml RPMI
1640 and the bottom chamber with 1ml RPMI 1640 supplemented
with 40mg/ml bovine serum albumin and incubated for 1 h at
37 1C. At the end of the incubation, albumin concentration in the
top chamber was determined using a bicinchoninic acid protein
assay kit (Sigma) with bovine serum albumin as a standard.
Urine albumin and creatinine assay
Urine albumin was determined by using a mouse albumin enzyme
linked immunosorbent assay Quantitation kit, according to the
manufacturer’s protocol (Bethyl Laboratories, Montgomery, TX,
USA).20 Urine creatinine was measured by using Quantichrome
creatinine assay kit, according to the protocol specified by the
manufacturer (BioAssay Systems, Hayward, CA, USA).
Statistical analyses
All data examined were expressed as mean±s.e.m. Statistical
analysis of the data was performed by using SigmaStat software
(Jandel Scientific, San Rafael, CA, USA). Comparison between
groups was carried out using one-way analysis of variance, followed
by Student–Newman–Keuls test. Po0.05 was considered statistically
significant.
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